Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?作者机构：Department of Medical Oncology Hospital Clínico San Carlos 28040 Madrid Spain
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2014年第20卷第20期
页 面：6092-6101页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Capecitabine 5-Fluorouracil Metastatic colorectal
摘 要：Fluoropyrimidines play a central role in the first-line treatment of metastatic colorectal cancer.Our aim was to review whether capecitabine was a safer,non-inferior,economically superior and more convenient alternative to 5-fluorouracil.Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin,irinotecan,or biological drugs-and has been found to have comparable efficacy and safety profiles.Furthermore,pharmacoeconomic data and patients’preferences for oral chemotherapy further favor capecitabine.Therefore,capecitabine appears to be an effective and safe alternative to fluorouracil in the first-line treatment of metastatic colorectal cancer.
维普期刊数据库